|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
|
Breast Carcinoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
17 double heterozygous (DH) breast cancer (BC) patients were identified upon the analysis of 5,391 affected women for recurrent Slavic mutations in BRCA1, CHEK2, NBN/NBS1, ATM, and BLM genes.
|
24800916 |
2014 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Breast cancer in female carriers of ATM gene alterations: outcome of adjuvant radiotherapy.
|
15450731 |
2004 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Breast cancer occurring in carriers of ATM variants is not associated with distinctive histopathological features and does not resemble the tumour phenotype commonly observed in BRCA1 mutation carriers.
|
17064299 |
2006 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Breast cancer stem cell-like cells are more sensitive to ionizing radiation than non-stem cells: role of ATM.
|
23185620 |
2012 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Breast cancer screening for ATM mutations carriers and referral to international experts in two undiagnosed patients were arranged.
|
29524103 |
2018 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
ATM was chosen for evaluation because of the increased radiosensitivity of cells derived from AT patients and obligate heterozygotes and the epidemiologic observation that AT carriers are at increased risk for radiation-induced breast cancer.
|
10561187 |
1999 |
|
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
ATM protein expression was analyzed by immunohistochemistry in 17 breast carcinomas with two monoclonal antibodies whose immunohistochemical use was first validated by comparing the immunoreactivity observed in spleen samples from ataxia telangiectasia and trauma patients.
|
10999741 |
2000 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
ATM missense mutations do not increase the risk of cancer overall or of breast cancer in the general population; however, we observed in exploratory analyses that ATM missense mutations may be associated with an increased risk of other cancer subtypes.
|
18565893 |
2008 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
ATM, a serine-threonine kinase, controls the cellular response to DNA double-strand breaks, and has been implicated in breast cancer risk.
|
18701470 |
2008 |
|
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
ATM was activated in 45% of normal tissue samples, 70% of preneoplastic lesions, and 14% of breast carcinomas.
|
19884805 |
2010 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
ATM polymorphisms IVS24-9delT, IVS38-8T>C, and 5557G>A in Mexican women with familial and/or early-onset breast cancer.
|
25014427 |
2014 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels.
|
25742469 |
2015 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
ATM kinase sustains HER2 tumorigenicity in breast cancer.
|
25881002 |
2015 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
ATM mutation prevalence in Spanish population highlights the importance of considering ATM pathogenic variants linked to breast cancer susceptibility.
|
27913932 |
2017 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
ATM participates in the signaling of telomere erosion, and inherited mutations in ATM have been associated with increased risk of cancer, particularly breast cancer.
|
28981872 |
2017 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
ATM heterozygotes are thought to have a high tendency to develop malignancies, such as breast cancer.
|
9592204 |
1998 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
A common assumption has been that the target for the LOH at 11q23.1 in breast carcinoma is the ATM gene, but the area studied has been too large, the density of markers too low, and the number of tumors studied has been too small to draw any firm conclusions.
|
10379867 |
1999 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A large proportion of the members of AT families are carriers of AT-causing gene mutations in ATM (Ataxia Telangiectasia Mutated), and it has been hypothesised that these otherwise healthy carriers are predisposed to breast cancer.
|
15942625 |
2005 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Activation of the ATM-Snail pathway promotes breast cancer metastasis.
|
22923499 |
2012 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Additionally, we summarized breast cancer risk associated with the following genetic factors: breast cancer susceptibility high-penetrance genes (BRCA1, BRCA2, p53, PTEN, ATM, NBS1 or LKB1) and low-penetrance genes such as cytochrome P450 genes (CYP1A1, CYP2D6, CYP19), glutathione S-transferase family (GSTM1, GSTP1), alcohol and one-carbon metabolism genes (ADH1C and MTHFR), DNA repair genes (XRCC1, XRCC3, ERCC4/XPF) and genes encoding cell signaling molecules (PR, ER, TNFalpha or HSP70).
|
15784178 |
2005 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
After Bonferroni correction (P ≤ 1.3 × 10-5), the strongest associations were detected in five pathways and gene sets, including maturity-onset diabetes of the young, regulation of beta-cell development, role of epidermal growth factor (EGF) receptor transactivation by G protein-coupled receptors in cardiac hypertrophy pathways, and the Nikolsky breast cancer chr17q11-q21 amplicon and Pujana ATM Pearson correlation coefficient (PCC) network gene sets.
|
30541042 |
2019 |